Kytril (Granisetron)

Kytril (granisetron) is employed to prevent and treat nausea and vomiting that arise from activation of serotonin 5‑HT3 receptors in the gastrointestinal tract and central nervous system.

• Chemotherapy‑induced nausea and vomiting: prevents acute and delayed episodes in patients receiving emetogenic chemotherapy.
• Postoperative nausea and vomiting: reduces incidence and severity of nausea and vomiting after surgical procedures.
• Radiation‑induced nausea and vomiting: controls nausea associated with radiotherapy to the abdomen or pelvis.
• Antiemetic prophylaxis in high‑risk patients: provides preventive coverage for individuals with known susceptibility to nausea and vomiting.

• Granisetron selectively antagonizes serotonin 5‑HT3 receptors located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By blocking these receptors, it inhibits the emetic signaling cascade triggered by chemotherapy, radiation, or surgical stimuli, thereby reducing the sensation of nausea and the act of vomiting.

Granisetron may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring shortly after dosing.
• Constipation: reduced bowel movements, sometimes requiring dietary adjustments.
• Dizziness: transient sensation of light‑headedness.
• Fatigue: feeling unusually tired or low in energy.

Serious or Rare Side Effects

• QT interval prolongation: may lead to cardiac arrhythmias, especially in susceptible patients.
• Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty.
• Cardiac arrhythmia: irregular heart rhythm requiring medical attention.
• Serotonin syndrome: rare condition with agitation, hyperthermia, and neuromuscular abnormalities.

Before prescribing Kytril, clinicians should consider several safety measures.

• Cardiac assessment: evaluate QT interval and cardiac history prior to initiation.
• Electrolyte monitoring: correct hypokalemia or hypomagnesemia to reduce arrhythmia risk.
• Hepatic impairment: use with caution in patients with liver dysfunction, adjusting dose if necessary.
• Hypersensitivity: discontinue immediately if signs of allergic reaction appear.
• Store at room temperature: keep in the original packaging, protect from moisture and light.

Granisetron can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Concomitant use with other QT‑prolonging agents: may increase risk of serious cardiac events.
• Use with apomorphine: can cause severe hypotension and syncope.
• Co‑administration with other 5‑HT3 antagonists: provides no additional benefit and may increase toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma concentrations.
• CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness.
• Drugs affecting electrolyte balance (e.g., diuretics): may heighten cardiac risk, especially QT prolongation.